На главную
Результаты поиска “Anca test for cancer”
Perspective on autoimmunity: a view from the ANCA vasculitis looking glass
 
59:24
Perspective on autoimmunity: a view from the ANCA vasculitis looking glass Air date: Wednesday, November 2, 2016, 3:00:00 PM Category: WALS - Wednesday Afternoon Lectures Runtime: 00:59:24 Description: NIH Director's Wednesday Afternoon Lecture Astute Clinician Lecture Dr. Falk's research probes questions focused on immune-mediated kidney diseases, especially glomerulonephritis. His clinical and basic science interests include both anti-neutrophil cytoplasmic autoantibody (ANCA) glomerulonephritis and small vessel vasculitis (SVV). A central objective of Falk's research is elucidating the causes of ANCA necrotizing and crescentic glomerulonephritis. Unraveling the cause of this disease requires considering a number of factors involved in the development of ANCA glomerulonephritis. Dr. Falk conceptualizes this process as opening the vasculitis lock with a key that has a number of "ridges and valleys" analogous to those factors that contribute to the development of this autoimmune disease. Dr. Falk participates in a research group that, in a large study over the last four years, has revealed a number of avenues of investigation and new approaches to ongoing questions that pertain not only to ANCA glomerulonephritis, but to the general fields of autoimmunity, inflammation and basic neutrophil and monocyte biology. This annual lecture started in 1998 and honors a U.S. scientist who has observed an unusual occurrence, and by investigating it, has opened an important new avenue of research. The lectureship exemplifies how astute clinical observations can lead to innovative research. Speakers are selected by the NIH Clinical Center. For more information go to https://oir.nih.gov/wals/2016-2017 Debug: Show Debug Author: Ronald J. Falk, M.D., Hugh and Nan Cullman Eminent Professor and Chair, Department of Medicine at University of North Carolina - Chapel Hill Permanent link: https://videocast.nih.gov/launch.asp?19984
Просмотров: 1350 nihvcast
ANCA Associated Vasculitides: Diagnosis & Treatment
 
21:57
In the second part of his core rheumatology lecture, Dr. Angelo Gaffo, Associate Director of the UAB Rheumatology Fellowship Training Program, discusses how to properly diagnose and treat ANCA associated vasculitides.
Просмотров: 1808 UAB Medicine
ANA Test - Diagnosing Systemic Rheumatic Disease (in Hindi)
 
03:40
एंटी न्यूक्लिअर एंटीबॉडी टेस्ट क्या है? यह टेस्ट क्योँ और कैसे किया जाता है? इस टेस्ट से करने से हमें किस प्रकार की जानकारी मिलती है? इस टेस्ट के रिजल्ट को कैसे पढ़ा जाता है? जानिए डॉ. अंकुश से एंटी न्यूक्लिअर एंटीबॉडी टेस्ट के बारे में। Antinuclear antibody test or ANA test is a blood test that helps diagnose systemic rheumatic diseases. Dr. Ankush describes about ANA test in Hindi, its procedure, test results and what information can be obtained from the test. Watch!
Просмотров: 52014 MediFee.com
Dr. Sasha Stanton: Auto-antibodies in breast cancer
 
05:32
The average woman has a one-in-eight chance of developing breast cancer over the course of her lifetime. There's always concern about the cancer coming back. Scientists at UW Medicine in Seattle have been developing a new vaccine to try to stop such recurrences. As part of their studies, the lab identified autoantibodies against several breast cancer stem cell proteins that show up in the blood of women with advanced breast cancer. And that’s the research to be discussed at an ASCO poster presentation. “We can look at the patient’s blood and tell just from that whether the patient is in more advances stages of breast cancer versus less advanced stages,” Dr. Sasha Stanton said. “We’re studying whether these antibodies are markers of aggression and possibly markers of progression of the cancer.” The autoantibodies are the body’s response to try to battle the cancer. After the poster presentation, Stanton and colleagues will continue to analyze whether a blood test for these autoantibodies might give medical providers a head start in identifying cancer in someone to provide earlier treatment. “The autoantibody response can be detected with just a small amount of the disease. I would hope that we ultimately could produce a biomarker so that we could tell someone who has been completely treated with breast cancer whether or not she’s at risk of recurrence sooner than we can right now through imaging and other tests," Stanton said. For the media: To interview Dr. Stanton, please contact please contact Walter Neary at wneary@uw.edu or 253-389-0736. For more stories from the UW Medicine Newsroom, check out https://newsroom.uw.edu/.
Просмотров: 43 UW Medicine
Marturie-Asistenta Medicala Diagnosticata Cu Cancer Este Vindecata-Claudia si Dan Taparlan
 
54:56
Marturie preluata cu acord de la emisiunea Vieti Transformate Marturie-Claudia si Dan Taparlan Vindecă-mă Tu, Doamne, şi voi fi vindecat; mântuieşte-mă Tu, şi voi fi mântuit; căci Tu eşti slava mea! Ieremia 17:14
Просмотров: 9998 Cybi
Innate molecules in the inflammation and cancer
 
01:02:52
Innate molecules in the inflammation and cancer Air date: Wednesday, November 9, 2016, 3:00:00 PM Category: WALS - Wednesday Afternoon Lectures Runtime: 01:02:51 Description: Wednesday Afternoon Lecture Series Dr. Cao has been investigating the molecular mechanisms for innate immune response and inflammation, and trying new approaches to cancer immunotherapy. As corresponding author, he published 226 original papers in peer-reviewed journals including Cell, Nature, Science, Nature Immunology, Immunity, Cancer Cell. Dr. Xuetao Cao is the current President of Chinese Academy of Medical Sciences and Peking Union Medical College. Dr. Cao’s laboratory focuses on the understanding of innate signaling in immunity and inflammation, identification of cell subsets and new molecules in dendritic cell (DC)-initiated immune response and cancer immunotherapy. His group has identified important mediators and regulators of innate signaling, characterized immune subsets with regulatory function in immunity, inflammation and cancer. Dr. Cao has won many awards in recognition of his scientific achievements and dedication to public services and China's medical research and education. He is widely recognized as a thought leader in promoting innovative and cross-disciplinary research at the national level and spearheads a number of initiatives. He is also proud to act as a bridge between China and the world on many occasions and has worked tirelessly to encourage international collaborations and enhance the global visibility of China's own research and development. For more information go to https://oir.nih.gov/wals/2016-2017/innate-molecules-inflammation-cancer Author: Xuetao Cao, M.D., Ph.D., Professor and President, Peking Union Medical College, Professor and President Chinese Academy of Medical Sciences Permanent link: https://videocast.nih.gov/launch.asp?19996
Просмотров: 1605 nihvcast
Combination therapies in cancer treatment – Video abstract [ID 61292]
 
03:11
Video abstract of a review paper “Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment” published in the open access journal ImmunoTargets and Therapy by Rajasekaran N, Chester C, Yonezawa A, et al. Abstract: The therapeutic efficacy of some anti-tumor monoclonal antibodies (mAbs) depends on the capacity of the mAb to recognize the tumor-associated antigen and induce cytotoxicity via a network of immune effector cells. This process of antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells is triggered by the interaction of the fragment crystallizable (Fc) portion of the mAb with the Fc receptors on effector cells like natural killer cells, macrophages, γδ T cells, and dendritic cells. By augmenting ADCC, the antitumor activity of mAbs can be significantly increased. Currently, identifying and developing therapeutic agents that enhance ADCC is a growing area of research. Combining existing tumor-targeting mAbs and ADCC-promoting agents that stimulate effector cells will translate to greater clinical responses. In this review, we discuss strategies for enhancing ADCC and emphasize the potential of combination treatments that include US Food and Drug Administration-approved mAbs and immunostimulatory therapeutics. Read the original article here: http://www.dovepress.com/enhancement-of-antibody-dependent-cell-mediated-cytotoxicity-a-new-era-peer-reviewed-article-ITT
Просмотров: 445 Dove Medical Press
Antibodies, Genome Stability, and Cancer
 
01:10:06
Antibodies, Genome Stability, and Cancer Air date: Wednesday, March 27, 2013, 3:00:00 PM Description: Wednesday Afternoon Lecture Series Dr. Alt and his group developed high-throughput, genome-wide translocation sequencing (HTGTS) to elucidate mechanisms that generate and join DNA double strand breaks (DSBs) and mediate translocations. He will discuss several new studies that employ the HTGTS approach and other approaches to address questions about the immunoglobulin heavy locus (IgH) class switch recombination (CSR) including how CSR DSBs are joined in a productive (deletional versus inversional) orientation in the chromosome; how IgH DSBs are synapsed for joining over several 100-kilobyte chromosomal distances to effect physiological levels of CSR; and the potential roles of the nuclear protein kinase ataxia telangiectasia mutated (ATM)-dependent DNA DSB response factors, including 53BP1, in the CSR process. He will also discuss the use of HTGTS to elucidate novel mechanisms that lead to V(D)J recombination-associated oncogenic chromosomal translocations and oncogene activation in ATM-deficient B- and T-cell lymphomas. Author: Frederick W. Alt, Ph.D., Charles A. Janeway Professor of Pediatrics at Boston Children's Hospital; Scientific Director of the Immune Disease Institute and Professor of Genetics at Harvard Medical School; Investigator, Howard Hughes Medical Institute Runtime: 01:10:05 Permanent link: http://videocast.nih.gov/launch.asp?17874
Просмотров: 1806 nihvcast
vasculitis
 
03:15
Patient presents with swollen legs and a rash. A short discussion of the workup, differential diagnosis, and initial treatment of this condition. Presumed vasculitis. ***many thanks for the patient allowing us to record this video***
Просмотров: 136686 DrER.tv
ANCA Vasculitis pathology
 
27:28
Просмотров: 209 Vikas Dutta
Eliab Anca - Cum stai cu credinta in Dumnezeu? Predica
 
26:34
#predicicrestine
Просмотров: 2130 Mesagerul Cinzecimii
Breast Cancer 360: Genomic Testing and New Directions for Treatment
 
59:31
During this presentation Dr. Nikhil Wagle explains what genomic testing is, how it’s used in breast cancer, where to get it and how to pay for it. We’ll explain how researchers use these tests today and the cutting-edge treatments available, often through clinical trials, based on the information gathered through genomic tests.
Просмотров: 345 Living Beyond Breast Cancer
Benefits of Genomic Testing in Breast Cancer
 
04:53
Просмотров: 149 OncLiveTV
Novel antibody helps patients with advanced gastric cancer live longer
 
02:43
Prof Al-Batran talks to ecancertv at ASCO 2016 about findings from a European phase II study which showed that the novel, first-in-class antibody IMAB362 can significantly extend median survival when added to standard chemotherapy (13.2 months vs. 8.4 months) for patients with advanced gastric cancer.
Просмотров: 983 ecancer
Former Miss Lithuania Reda Karosiene & former Miss Romania Anca Verma savouring Olialia Cheesecake
 
01:25
Former Miss Lithuania Reda Karosiene & former Miss Romania Anca Verma savouring Olialia Cheesecake at the residence of Abhishek Verma in New Delhi, India on September 9, 2018 #VermaFamilyDiary
Просмотров: 376 The Verma Family
These Blood Tests Offer More than Your Doctor Knows!
 
02:39
Get our free email newsletter at http://www.ihealthtube.com/content/newsletter Dr. Joyce Johnson discusses the blood tests and in-depth results that she offers and what you can learn from them. She also discusses particular courses of action based on the results of these tests that most doctors don't know about!
Просмотров: 4298 iHealthTube.com
Metastasis, Cancer Nomenclature, Tumor Nomenclature Lymphatic Spread Metalloproteinase
 
05:48
http://www.stomponstep1.com/metastasis-cancer-nomenclature-tumor-nomenclature/ Mesenchymal (connective tissue, blood or lymphatic tissue) cancers have a specific naming system. There is a prefix for different types of tissue that make up the tumor and a suffix to signify whether it is benign or malignant. However, Cancers of blood cells (Leukemia) and lymph nodes (Lymphoma), both of which are always malignant, do not follow this pattern. Prefix + OMA = Benign Mesenchymal Cancer Prefix + SARCOMA = Malignant Mesenchymal Cancer Mesenchymal Cancer Prefix • Lipo- = Fat • Osteo- = Bone • Fib- = Fibrous Tissue • Chondro- = Cartilage • Hemangio- = Blood vessel • Leiomyo- = smooth muscle • Rhabdomyo- = striated muscle Cancers that originate from epithelium (glands and surface/cavity lining) have a naming system that is more complicated. Benign epithelial cancers that contain glandular tissue (such as prostate, adrenal glands and certain types of colon cancer) are called Adenomas. Adenomas often grow into the lumen of whatever organ they are in forming a Polyp. Cystadenomas are hollow cysts-like cancers that are usually filled with fluid. Benign cancers of stratified squamous epithelium that form “cauliflower” finger like projections are called Papillomas. Malignant epithelial cancers are called Carcinomas. Metastasis is the spread of a cancer from the original tumor location to “distant” sites in the body. This is generally thought of as being separate from cancer invasion, which is the direct extension of a cancer across an organ or to neighboring organs. Invasion is a tumor growing in size and taking up more space, while metastasis involves migration to a completely new site. Metastasis is the most important prognostic factor for a cancer and is represented by the cancer’s Stage (More important than the cancer’s level of differentiation or grade). Metastasis is usually via the lymphatic system or the blood vessels. In this way, the cancer cells use the lymph or blood as a highway to get to other sites in the body. Carcinomas tend to spread via the lymph while sarcomas more commonly spread via blood, but there are numerous exceptions to this general rule. Carcinoma = Lymphatic Spread Sarcoma = Hematologic (Blood) Spread To be able to spread cancer cells need certain abilities which are gained via additional mutations. These mutations allow the cancer cells to break away from the primary tumor, “eat” through the basement membrane (Type IV Collengenase), “eat” through the extracellular matrix (Metalloproteinases), enter the lymphatics/blood, survive travel in the fluid, exit lymphatics/blood, and survive in the new site. The original mass is called the primary tumor while all subsequent masses are secondary tumors. Cancers can spread almost anywhere once they are in the lymph or blood, but the location of secondary tumor sites is not random. The circulatory anatomy and how accommodating certain tissues are to cancers mean that secondary tumors arise in certain areas most often. Due to these tendencies the most likely location of metastasis can often be predicted. Secondary Tumor: Most likely Primary Tumor: • Liver GI cancers like colon cancer • Brain (gray-white junction) Lung & Breast • Bone (spine) Prostate (blastic), Lung (lytic) & Breast (Both) • Lung Breast Liver Metastasis is most common among cancers that arise in the GI tract (Like colon cancer), which makes sense as the liver receives blood from the GI tract through portal venous system. The Brain Metastasis usually present at the Gray-White matter junction. This is because the width of the vessels changes quickly at this junction and metastatic “emboli” are more likely to lodge here. Metastatic brain cancer generally presents as multiple lesions while a primary brain cancer is usually a single lesion. Lung and Breast are the most common primary site for brain metastasis. Lung Metastasis is most often from breast cancer. Primary bone cancers are rare, but Metastasis to Bone is relatively common. Metastasis to the spine (resulting in low back pain) from the prostate is a common presentation in step 1 questions. Different primary tumors have unique secondary bone cancer characteristics. Lytic lesions are where increased osteoclast activity eats away at the bone and releases calcium (seen as hypercalcemia). Blastic Lesions are where increased osteoblastic activity results in more bone being laid down than normal. 1o Lung Cancer --) osteoLytic 2o Bone Cancer 1o Prostate Cancer --) osteoblastic 2o Bone Cancer 1o Breast Cancer --) Both lytic and blastic 2o Bone Cancer Now that you have finished this video you should check out the next video in the Cell Injury, Cell Death & Cancer sections which covers Cell Cycle (http://www.stomponstep1.com/cell-cycle-interphase-labile-cell-stable-permanent-tissue/)
Просмотров: 8212 Stomp On Step 1
WOWBIZ (18.04.2018) - Confruntarea dintre Anca si Alina, la un pas sa degenereze!  Partea 3
 
14:57
WOWBIZ (18.04.2018) - Confruntarea dintre Anca si Alina, la un pas sa degenereze! Ce cuvinte grele si-au aruncat? Partea 3 Ne puteti urmari si pe: http://www.kanald.ro/ http://www.wowbiz.ro/ Copyright © Toate drepturile rezervate.
Просмотров: 111765 Kanal D Romania
Esophageal Motility Disorders
 
25:08
This Masters in Medicine webcast is one in a three-part series by Dr. Edgar Achkar. This webcast reviews esophageal motility disorders, including dysphagia and achalasia. Take the opportunity to also learn from Dr. Achkar in Medical Management of GERD and Eosinophilic Esophagitis. To learn more about the Masters in Medicine series or to claim CME credit, visit http://www.ccfcme.org/Masters The video was produced by the Cleveland Clinic Foundation Center for Continuing Education.
Просмотров: 50937 ClevelandClinicCME
Using the Immune System to Fight Cancer, Yvonne Paterson Lecture
 
01:03:58
Yvonne Paterson is Professor of Microbiology in the Perelman School of Medicine. She will review various approaches to immunotherapy including, adoptive T cell and antibody therapies, checkpoint inhibitors and cancer vaccines. Immunotherapy is a type of cancer treatment designed to boost or augment the body’s natural defenses to fight cancer. It uses natural immune system components either made in the laboratory or by the body itself to improve, target or restore the body’s ability to recognize cancer as a foreign attacker. Recent advances were described by “Science” magazine, in 2013, as the breakthrough of the year. Wednesday, October 26, 2016, 12PM Hourglass Room in the University Club in the Inn at Penn
Просмотров: 428 Penn Arts & Sciences
Positive Herpes Igg Test Means You Have Fungal Infections!
 
14:14
Join us on Facebook: http://tinyurl.com/fungusisthecause The Healing Revolution http://mycolonisfilthy.com 404.919.9671
Просмотров: 7177 oxygen2295
Clinical Cancer Geneticist: Noah D. Kauff, MD
 
01:32
Clinical cancer geneticist Noah D. Kauff, MD practices at the Duke Cancer Center in Durham. Get to know him in this video and learn more at https://www.dukehealth.org/find-doctors-physicians/noah-d-kauff-md About Dr. Kauff My clinical areas of expertise include cancer risk counseling, screening for and prevention of inherited cancers, and providing gynecologic care to cancer patients. Since 2005, I have served on the Cancer Prevention and Control Committee of the Gynecologic Oncology Group and NRG Oncology, and I currently co-chair the Prevention/Behavioral/Epidemiology working group. Previously I have served on the Education Committee of the Society of Gynecologic Oncologists, the Editorial Board of the Journal of Clinical Oncology, and the Committee on Genetics of the American College of Obstetricians and Gynecologists. I am also the Duke Cancer Institute representative to the National Comprehensive Cancer Network Panel - Genetic/Familial High-Risk Assessment: Breast and Ovarian.
Просмотров: 248 Duke Health
MONOCLONAL ANTIBODY
 
01:36
INTRODUCTION:- MONOCLONAL ANTIBODY- (mAb) are antibodies that are identical because they were produced by one type of immune cell, all clones of a single parent cell. Production of long-lasting monoclonal antibodies is a recent invention and it is used in both medicine and research. Monoclonal antibodies can be produced in specialized cells through a technique now popularly known as Hybridoma technology. HISTORICAL BACKGROUND:- 1890 Von Behring and Kitasato discovered the serum of vaccinated persons contained certain substances, termed antibodies. Porter isolated fragment of antigen binding (Fab) and fragment crystalline (Fc) from rabbit y-globulin. 1964 Littlefield developed a way to isolate hybrid cells from 2 parent cell lines using the hypoxanthine-aminopterin-thymidine (HAT) selection media. 1975 Kohler and Milstein provided the most outstanding proof of the clonal selection theory by fusion of normal and malignant cells. This resulted in the first monoclonal antibodies, for which they received the Nobel Prize in 1984. MONOCLONAL ANTIBODY PRODUCTION STEPS:- Inject a mouse with a specific antigen to stimulate its immune system to produce necessary antibodies. Extract mouse spleen cells (containing B-lymphocytes) and culture them in the lab. Extract mouse tumour cells, which grow continuously, and culture them in the lab. Mix spleen cells and tumour cells on the same plate and culture. Add polyethylene glycol – this causes some B-lymphocytes to fuse with tumour cells to produce a hybrid cell called a hybridoma. Grow the cells under conditions that allow only hybridoma cells to survive. Extract the cells, culture them separately and test the medium around each cell for the specific antibody of interest. Culture the cells making the desired antibody and use as needed. TYPE OF MONOCLONAL ANTIBODY:- Murine source mAbs:- Rodent mAbs with excellent affinities and specificities, generated using conventional hybridoma technology. Clinical efficacy compromised by HAMA(human anti murine antibody) response, which lead to allergic or immune complex hypersensitivities. Chimeric mAbs:- Chimers combine the human constant regions with the intact rodent variable regions. Affinity and specificity unchanged. Also cause human antichimeric antibody response (30% murine resource). Humanized mAbs:- Contained only the CDRs of the rodent variable region grafted onto human variable region framework. APPLICATION:- In clinical pharmacology, immunosuppressant's in transplantation and autoimmune reactions and a targeting vehicle for treatment of cancers. mAbs are utilized in diagnostic kits for the diagnosis of various infectious diseases, detecting pregnancy, monitoring drug levels, matching histocompatibility antigen, detecting diabetes, and in cancer. Monoclonal antibodies to define mouse and human differentiation and tumour antigens. Improving the out come of bone marrow transplantation by using mAbs. Labelling and precise identification of specialized cells such as neurons. In the preparation of specific vaccines against viral strains. In enzyme genetics, enzyme engineering and enzyme purification. In determination the structure of cell membrane. In cell biology studies, such as anti-tubulin and anti-actin antibodies. ADVANTAGE AND DISADVANTAGE:- Pure one molecular species only. Specificity for one antigenic determinant. Antibodies with high avidity can be produced. In vitro and In vivo production is possible with high production rate. Production of cell lines to individual components of a mixture is possible. The method is more time consuming and costly.
Просмотров: 979 Neel Prakash
Blood test measuring natural killer cell activity may predict patients at risk for colorectal cancer
 
05:57
Katia Betito, PhD, Vice president, scientific affairs, ATGen Canada Inc., discusses a new blood test for the detection of colorectal cancer (CRC): Measurement of natural killer cell activity (NKA) in patients undergoing colonoscopy. MDLinx Conference Coverage - Digestive Disease Week (DDW): http://www.mdlinx.com/gastroenterology/conference-interview/digestive-disease-week-ddw-/232079 MDLinx: http://www.mdlinx.com/ Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/ M3 USA: http://usa.m3.com/ Follow MDLinx: Facebook - https://www.facebook.com/MDLinx Twitter - https://twitter.com/MDLinx Google+ - https://plus.google.com/+Mdlinx/
Просмотров: 182 MDLinx
Dr. Sosa Discusses Molecular Testing in Thyroid Cancer
 
02:35
Julie A. Sosa, MD, MS, professor of surgery and medicine, chief of endocrine surgery, Duke University, discusses molecular testing for thyroid cancer. View more from the ATA Annual Meeting, at http://www.onclive.com/conference-coverage/ata-2014
Просмотров: 567 OncLiveTV
Vasculitis: Inflamed Blood Vessels + 4 Natural Treatments
 
05:30
Vasculitis: Inflamed Blood Vessels + 4 Natural Treatments
Просмотров: 262 annette meade
ANA TEST KIS LIYE KRATE HAIN?
 
04:38
ANTI NUCLEAR ANTIBODY (ANA) TEST KYA HAI? ESE KIS LIYE KIYA JATA HAI? KIS-KIS METHOD SE KIYA JATA HAI?KIS-KIS DISEASE KE LIYE KIYA JATA HAI EN SAB KE BARE ME ES VIDEO ME BTAYA GYA HAI. LINK-https://youtu.be/yEINrpNKYHE
Просмотров: 13441 Pathology knowledge
How to test for cardiovascular inflammation: MPO Myeloperoxidase - "the Joker"
 
07:42
Please watch: "(905) Mitochondria: Central Role in Aging 2018 (and how to reverse it)( warning - geeky)- FORD BREWER " https://www.youtube.com/watch?v=mTKM0Lh078A --~-- Join the PrevMed Community: https://mailchi.mp/1224fb9e00e7/prevmed_community 4th in a series of cardiovascular inflammation testing: Myeloperoxidase. There is an unusual problem here that causes some fear and drama. This test is the most common FALSE POSITIVE. However, even experienced practitioners call it the joker. By calling it the joker, they mean it can kill even when all other types of inflammatory markers are negative. So, I simply tell patients that. And I tell them we'll repeat the test. And meanwhile, I start them on the treatment - Melatonin. Myeloperoxidase is an enzyme released by the granules of neutrophils (also called granular leukocytes or polymorphonucleocytes). This enzyme kills and digests foreign bodies. It gives the green tint to mucus. About Dr. Brewer - Ford Brewer is a physician that started as an Emergency Doctor. After seeing too many patients coming in dead from early heart attacks, he went to Johns Hopkins to learn Preventive Medicine. He went on the run the post-graduate training program (residency) in Preventive Medicine at Hopkins. From there, he made a career of practicing and managing preventive medicine and primary care clinics. His later role in this area was Chief Medical Officer for Premise, which has over 500 primary care/ prevention clinics. He was also the Chief Medical Officer for MDLIVE, the second largest telemedicine company. More recently, he founded PrevMed, a heart attack, stroke, and diabetes prevention clinic. At PrevMed, we focus on heart attack and stroke and Type 2 diabetes prevention by reducing or eliminating risk through attentive care and state-of-the-art genetic testing, imaging, labs and telemedicine options. We serve patients who have already experienced an event as well as those have not developed a diagnosis or event. Our team of senior clinicians includes internationally recognized leaders in the research and treatment of cardiovascular disease, preventive medicine and wellness. We also provide preventive medicine by telemedicine technology to over 30 states. Contact Dr. Brewer at info@prevmedheartrisk.com or visit http://prevmedheartrisk.com.
Просмотров: 881 Ford Brewer
Thyroid Cancer: Metastatic Disease, How Much Radioactive Iodine. Dr. Kwak. ThyCa Conference
 
01:16:03
Treatment of Metastatic Thyroid Cancer: How Much Radioactive Iodine Should Patients Receive. Jennifer Kwak, M.D., Nuclear Medicine Physician
Campanie pentru copiii bolnavi de cancer - partea 2
 
32:24
www.ztv.ro primar Simleu Silvaniei Septimiu Catalin Turcas reporter Anca Schlachter operator imagine Arnold Schlachter
Просмотров: 367 ZTV
ANCA Live Update - August 2, 2013
 
14:31
ANCA Live Update - August 2, 2013 Update about various issues that the ANCA dealt with this past week
Anti Idiotypic Antibodies – A Powerful Tool for Antibody Drug Studies
 
39:56
Anti-idiotype antibodies (anti-IDs) serve as powerful tools for such studies, as they are able to differentiate antibody drug from endogenous antibodies and allow tracking of antibody drug in biological fluid. However, it has been challenging to develop highly specific and sensitive anti-IDs due to the low percentage of anti-IDs relative to other naturally-occurring antibodies in immunized animals. This webinar will take an in-depth look into the field of anti-IDs, including the obstacles and solutions surrounding the generation of highly sensitive, highly specific anti-IDs, as well as their use in vaccine development, PK/PD and immunogenicity studies.
Просмотров: 4673 GenScript USA Inc.
Dr. Ara Chalian: The ANCA is Your Voice in Congress
 
00:16
Pennsylvania physician and local ANCA leader Dr. Ara Chalian shares his reasons for supporting ANCA Telethon 2014. On June 1st, the 2014 ANCA Telethon will bring thousands of people together from coast to coast. On that day, we will celebrate our accomplishments and reach out to you for your assistance in order to continue our efforts. Your generosity will enable us to educate, motivate, and activate our community and continue our educational, charitable, and civic involvement programs from our nation's capital to our local communities. Pledge Today! Call (855) 208-2622 Go online to www.ancatelethon.org Text "ANCA" to 80888
Breast Cancer Marathon
 
01:59
Marathons, 10-K's, bike rides and telethons. Events to raise money for diseases like cancer seem to happen all the time. Many of these fund raisers really do make a difference in the race to find a cure. More on how one marathon is raising money to help researchers learn about cancer genes so they can work towards developing better treatments.
Просмотров: 848 Mayo Clinic
Sorrento Therapeutics (SRNE) Developing Therapeutic Antibody Library
 
07:50
Dave Gentry interviews Dr. Henry Ji, CEO of Sorrento Therapeutics, Inc. (NasdaqCM: SRNE), a late-stage clinical oncology company developing new treatments for cancer and associated pain, on "The RedChip Money Report: Small Stocks Big Money." "The RedChip Money Report"™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The weekly program airs on Fox Business as well as Bloomberg UK, Bloomberg Europe, and Bloomberg Asia. For more information, visit: http://www.redchip.com/tv
Просмотров: 778 RedChip Companies
Radioactive Iodine Uptake Test: Pros and Cons
 
05:16
http://www.GravesDiseaseBook.com. This video will discuss some of the benefits and disadvantages of receiving the radioactive iodine uptake test, which is recommended by many endocrinologist for people with hyperthyroid conditions.
Просмотров: 8298 HyperthyroidismCure
Hip Muscle Anatomy, Support & Movement
 
09:15
Hip Muscle Anatomy, Support & Movement To See th other video: Causes, Symptoms, and Treatments of Scoliosis http://www.youtube.com/watch?v=U4Jk8qNKI_U Mechanism and Procedur Mammograms to Screening Breast Cancer http://www.youtube.com/watch?v=QnDH0_vrY-Y Neuromuscular Junction Process in Skeletal Muscle http://www.youtube.com/watch?v=DxShix3Mqow Anatomy of Neuromuscular Junctions NMJs How Muscles Work http://www.youtube.com/watch?v=jbD4IHJofeQ Human Skeletal Muscle in Motion http://www.youtube.com/watch?v=CqIF-yjH-No Mechanism Glumerula Filtration in Human Kidneys http://www.youtube.com/watch?v=skAux8oNKNw Human Anatomy : 3D Animation Scapula Joint Movements http://www.youtube.com/watch?v=h66cGNe2IPM Human Anatomy : 3D Animation Shoulder Joint Movements http://www.youtube.com/watch?v=kddfMp8wih4 Human Anatomy : 3D Animation Elbow Joint Movements http://www.youtube.com/watch?v=eJ0HdV3ZSQk Translated titles: Hüfte Muskelanatomie, Unterstützung und Bewegung हिप मांसपेशी शरीर रचना, समर्थन और आंदोलन Heupspieranatomie, ondersteuning en beweging Hip anatomya ng kalamnan, suporta at paggalaw 엉덩이 근육 해부학, 지원 및 운동 Anatomía, soporte y movimiento de los músculos de la cadera تشريح عضلة الورك ، الدعم والحركة হিপ পেশী শারীরস্থান, সমর্থন এবং আন্দোলন हिप मांसपेशिहरु को रचना, समर्थन र आंदोलन ہپ پٹھوں کی انااتومی، حمایت اور تحریک
Просмотров: 14608 Human Physiology
Free PSA ELISA kit
 
01:59
http://www.rapidtest.com/index.php?i=Free-PSA-ELISA-kit&id=42&cat=9 Cancer ELISA kits: Free PSA ELISA kit ELISA kit manufacturer and ELISA kit supplier: Diagnostic Automation, Inc., Tel:818 591 3030, USA.
Просмотров: 345 cancerELISAkit
The Antibodies Song
 
01:45
This song is to help us remember autoantibodies and the autoimmune diseases they cause. It is inspired by Wakko Warner's The 50 States and their capitals song. Lyrics: The Antibodies Song ANA and Anti-Smith are for Lupus Rheumatoid Factor Rheumatoid arthritis Theres anti-centromere if youre looking for CREST Double stranded DNA is Lupus nephritis Anti-SSA and anti-SSB are the antibodies for Sjogrens Disease Anti-RNP for MCTD Anti-basement membrane is for Goodpastures disease Anti-jo 1 for polymyositis ANCA can be found in microscopic polyarteritis Anti-GAD diabetes mellitus And Anti smooth muscles in autoimmune hepatitis Anti-mitochondrial PBC In Celiac sprue look for Anti-TTG Anti-histone drug induced SLE in Scleroderma youll find SCL 70 Lets say that a patient has a PE Youll want to send Anti cardiolipin antibody As long as youre working up a hypercoagulable state Send Lupus anticoagulant and APLA, mate TSI is in Graves disease Now lets say your patient has a high MCV Pernicious anemia it may be Send Anti-parietal cell Ab Anti TPO Hashimotos thyroiditis Acetylcholine receptor Myasthenia gravis Finally Antiplatelet antibody Is not needed to diagnose ITP Thats all the antibodies for now
Просмотров: 35013 Stoop
Mr bean na murit este anca an viata
 
03:13
Like supscribe si aboneazate
Просмотров: 209 Laur Game Station Ro
Glomerular diseases
 
18:01
This is a summary of diseases that affect the glomerulus of the kidney, including those that case nephrotic and nephritic syndromes. I created this presentation with Google Slides. Image were created or taken from Wikimedia Commons I created this video with the YouTube Video Editor. ADDITIONAL TAGS: Glomerular diseases Minimal change disease Focal segmental glomerulosclerosis Membranous glomerulonephritis Diabetic nephropathy Amyloid nephropathy Lupus nephritis Membranoproliferative glomerulonephritis IgA nephropathy Acute postinfectious glomerulonephritis Anti-GBM disease ANCA glomerulonephritis Nephrotic Nephritic Systemic Primary glomerular disease with nephrotic syndrome Most common in children, especially young children LM: “minimal change” -- looks normal IF: negative (no immune complex deposition) EM: foot process effacement, see figure secondary causes: cancer, infection, drugs, atopy (hyperallergic) Associated with lymphoma and use of NSAIDs Primary glomerular disease with nephrotic syndrome Focal means some glomeruli, segmental means not all of glomerulus LM: segmental glomerular scarring, see hyaline material (deposits from plasma) IF: positive for Ig and complement, granular appearance EM: segmental effacement Primary FSGS is idiopathic Secondary causes: genetic, infection (HIV, parvovirus), drugs (heroin), sickle cell, obesity Most common in blacks Primary glomerular disease with nephrotic syndrome LM: capillary wall thickening with IgG and C3 immune complexes IF: positive for IgG and C3 in the capillary, granular EM: immune complexes in subEPIthelial space Primary cause: Ab against anti-phospholipase A2 receptor Secondary causes: cancer, lupus, NSAIDs, HBV, Hep B, syphilis… Ag can be Hep B or cancer Secondary nephropathy with nephrotic syndrome; DM is primarily systemic disease Caused by DM types I and II → accumulation of glycosylated plasma protein in GBM and mesangium LM: mesangial expansion and KW nodules IF: linear staining of IgG EM: thickened GBM Treatment is reduce blood sugar, lower blood pressure, avoid nephrotoxins Most common cause for end stage renal disease in United States Secondary nephropathy with nephrotic syndrome; amyloidosis is primarily a systemic disease Caused by accumulation of polypeptides (especially AL and AA amyloid) LM: thickening of mesangium amorphous pale pink stuff in glomerulus, confirm with Congo Red stain IF: monoclonal staining of accumulated amyloid protein EM: randomly arranged fibrils Associated with rheumatoid arthritis and multiple myeloma Ranked by class: I (best) to VI (worst) Antigen antibody complexes deposit in gloms, activate complement which leads to proliferation of mesangium and infiltration of PMNs LM: endocapillary and mesangial proliferation and sometimes crescents IF: granular pattern, everything lights up! “full house pattern” EM: deposits anywhere and everywhere Hypocomplementemia - both C3 and C4 blood levels are low Presents with nephritic and/or nephrotic syndrome; kind of in between Type I is immune complex and C3 deposits Caused by bacterial infection, hep C infection, malignancies Type II is just C3 deposits but no Ig Caused by complement dysregulation LM: capillary wall thickening with hypercellularity IF: immune complexes and/or C3 granular deposits causing hypocomplementemia EM: same deposits (subendo and BM) Deposits of IgA alone or with other Igs, in mesangium Activates complement, which causes proliferation of mesangial cells LM: mesangial hypercellularity IF: IgA positive, granular pattern in the mesangium EM: mesangial deposits Primary IgA nephropathy is idiopathic Can be part of systemic disease IgA vasculitis; related to Henoch– Schönlein purpura Occurs few weeks after infection; most often follows strep or staph LM: endocapillary and mesangial hypercellularity and PMNs IF: pos for C3 in capillary walls, granular EM: subepithelial humps Hypocomplementemia; low C3 levels Treatment is supportive Nephritic Caused by autoAb to glomerular basement membrane Abs recruit complement and lymphocytes → damages capillary → proliferation and accumulation in Bowman’s space → crescent LM: crescent formation IF: pos for IgG in linear pattern EM: normal Disease is called Goodpasture’s syndrome when presents with both kidney and lung involvement LM: crescents, necrosis IF: pauci-immune; not much lights up EM: normal Associated diseases: Granulomatosis with polyangiitis (GPA); Wegener's; PR3 Eosinophilic granulomatosis with polyangiitis (eGPA); Churg–Strauss churg Strauss Microscopic polyangiitis (MPA)
Просмотров: 19155 MedLecturesMadeEasy
C4 test videoscribe
 
00:18
this is my description
Просмотров: 42 Matthew Marchyok
Zeolite Heavy Metal Cleanse (Detox) Natural Cancer Treatment
 
01:15
To learn more about Zeolite or to order visit http://regalsupplements.com?AFFID=328623
Просмотров: 49 Nature's Essential
HOW KIDNEY DISEASE SAVED MY LIFE| Victoria R.
 
16:52
This is my first video on YouTube it is about my diagnosis with ANCA vasulitis and anti GBM. I hope you enjoy!
Просмотров: 409 Victoria R.
Lab Tests Plus - Food IgG Test (using dry blood spot)
 
01:55
http://labtestsplus.com Dr. Kurt Woeller discusses how the Food IgG Test can help to determine food sensitivities for up to 90 different foods. Food sensitivities can cause headaches, chronic fatigue, joint pain, inflammation,and more. You can order the Food IgG test at LabTestsPlus.com. When you order lab tests from LabTestsPlus.com, you also receive a doctor's written review of the test, plus a recommended course of action, plus the doctor's only codes you will need to order professional grade supplements if required. http://labtestsplus.com
Просмотров: 336 Lab Tests Plus
Natural Haircare Previa - Anca
 
00:41
Seminar Natural Haircare Previa Cluj-Napoca - 15.10.2017
Просмотров: 54 Sentera Cosmetice Profesionale
Ovarian Cancer: Progression and Treatment Options
 
04:41
Unfortunately in this day and age, the majority of ovarian cancers present at the late stage. Statistically 80% of all ovarian cancers present at an advanced stage either stage 3 or 4. Treatment options for those patients usually requires a combination of a surgery and chemotherapy. New advances in ovarian cancer at this point in time really rely upon what we call adjuvant treatment for ovary cancer and what I mean by that is surgery for ovarian cancer as for several, several decades, its main goal is to what we call surgically remove the cancer and what that means is remove all of the macroscopic or all of the disease that we can see or touch at the time of surgery. Many times we can't remove every single piece of cancer that we can see or feel, but the goal is to leave as little a nodule of cancer behind following surgery and what we strive to do is leave any cancer behind that will be smaller than 1 cm that's the goal and from a surgical standpoint that may require removal of parts of the intestinal tract or urinary tract, etc. The surgery's goal is to remove the large pieces of cancer and leave the smallest amount of residual tumor behind as we can and that's what chemotherapy is for. Chemotherapy works better on small implants of cancer than it does on large implants of cancer. For many patients, we are employing something called intraperitoneal chemotherapy which is when a patient receiving chemotherapy receives a combination of some intravenous chemotherapy which is a standard traditional approach and some patients will receive a combination where they also receive intraperitoneal chemotherapy or a lot of patients consider this a belly wash chemotherapy where there is a port implanted in the abdomen where we infuse chemotherapy directly into the abdominal cavity and in patient that can tolerate and be administered intraperitoneal chemotherapy, it has been shown that these patients actually do better and have a longer survival rate. And so on this day and age that's what most of us strive to do is to have an excellent surgical result followed by a combination intravenous and intraperitoneal chemotherapy. The challenge to the medical environment is to catch ovarian cancer at an earlier stage and there are some new blood tests that are doing a better job with that than we did ten years ago. There are some new screening algorithms or triage algorithms for an ovarian mass that help patients get to a trained professional such as GYN oncologist for their initial operation which in this time still is the most important aspect of a woman's care with ovarian cancer is that her initial diagnosis and initial management is performed by a GYN oncologist. Most notably there are some blood tests. One's called the OVA 1, which is a blood test that screens for five different analytes in a woman's blood to help us dictate whether or not an ovarian mass is cancer or not and that test does do a better job than some of the other more traditional approaches that we use. Again another challenge to women that have been found to have an ovarian mass is to definitely seek out the right physician. The good news is a vast majority of an ovarian mass that is seen on CT scan or ultrasound is benign. It is not a cancer, the vast majority of a time. The challenge for a medical team is to weed out who are those cancers and who is not and certainly seek second opinions, seek out GYN oncologists, if you have an ovarian mass for a second opinion or a surgical consultation, because it's important that you get the best preoperative evaluation in the event that it is a cancer that you are taking care of by the right medical professional. Learn more about Dr. McDonald: http://presbyteriangyncancer.org/?id=5013&sid=123
Просмотров: 132 Best Doctors